Literature DB >> 53994

Long-term treatment of ventricular arrhythmias with oral mexiletine.

R G Talbot, D G Julian, L F Prescott.   

Abstract

Twenty-four patients with ventricular arrhythmias were treated with oral mexiletine for periods of from one to 16 months (total 10.4 patient-years). In 19 patients arrhythmias were satisfactorily controlled and plasma levels previously shown to be within the therapeutic range were maintained on an 8 hourly regimen. The drug was well tolerated in most patients and regular hematological and biochemical screening revealed no problems of toxicity.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 53994     DOI: 10.1016/s0002-8703(76)80435-8

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  17 in total

1.  A rapid method for the determination of plasma mexiletine levels by gas chromatography.

Authors:  I D Bradbrook; C James; H J Rogers
Journal:  Br J Clin Pharmacol       Date:  1977-06       Impact factor: 4.335

2.  [Treatment with mexiletine. Clinical and pharmacokinetic studies].

Authors:  H Breithaupt; A Schmidt
Journal:  Klin Wochenschr       Date:  1988-06-01

Review 3.  New antiarrhythmic drugs: their place in therapy.

Authors:  D L Keefe; R E Kates; D C Harrison
Journal:  Drugs       Date:  1981-11       Impact factor: 9.546

4.  Long-term oral antiarrhythmic therapy with mexiletine.

Authors:  N P Campbell; J F Pantridge; A A Adgey
Journal:  Br Heart J       Date:  1978-07

5.  [Mexiletine--findings in animal experiments on its antiarrhythmic and electrophysiological effects in the heart (author's transl)].

Authors:  K Haap; H Antoni
Journal:  Klin Wochenschr       Date:  1978-02-15

6.  Antiarrhythmic drugs: clinical pharmacology and therapeutic uses.

Authors:  J L Anderson; D C Harrison; P J Meffin; R A Winkle
Journal:  Drugs       Date:  1978-04       Impact factor: 9.546

Review 7.  Mexiletine: a review of its pharmacological properties and therapeutic efficacy in arrhythmias.

Authors:  C Y Chew; J Collett; B N Singh
Journal:  Drugs       Date:  1979-03       Impact factor: 9.546

8.  Efficacy of oral mexiletine in the prevention of exercise-induced ventricular ectopic activity.

Authors:  G Koch; B Lindström
Journal:  Eur J Clin Pharmacol       Date:  1978-06-19       Impact factor: 2.953

9.  Combination antiarrhythmic treatment among class Ia, Ib, and II agents for ventricular arrhythmias.

Authors:  T Tanabe
Journal:  Cardiovasc Drugs Ther       Date:  1991-08       Impact factor: 3.727

10.  The metabolism of mexiletine in relation to the debrisoquine/sparteine-type polymorphism of drug oxidation.

Authors:  F Broly; N Vandamme; C Libersa; M Lhermitte
Journal:  Br J Clin Pharmacol       Date:  1991-10       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.